Radioprotection of mouse hemopoiesis by dipyridamole and adenosine monophosphate in fractionated treatment
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
7899555
Knihovny.cz E-resources
- MeSH
- Adenosine Monophosphate pharmacology toxicity MeSH
- Dipyridamole pharmacology toxicity MeSH
- Hematopoiesis radiation effects MeSH
- Survival Rate MeSH
- Mice, Inbred C57BL MeSH
- Mice, Inbred CBA MeSH
- Mice MeSH
- Radiation-Protective Agents pharmacology MeSH
- Spleen radiation effects MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adenosine Monophosphate MeSH
- Dipyridamole MeSH
- Radiation-Protective Agents MeSH
The purpose of the studies reported here was to investigate the ability of the combined administration of dipyridamole and adenosine monophosphate, drugs known to elevate extracellular adenosine, to protect mice undergoing treatment with fractionated irradiation (five doses of 2 or 3 Gy each) given at 24-h intervals. Based on observations of hemopoietic recovery (endogenous hemopoietic spleen colony formation, marrow granulocyte-macrophage colony-forming cells, peripheral blood cells) after the completion of fractionated irradiation and on survival studies, it was demonstrated that the repeated administration of the drugs 60 min before each of the radiation fractions mitigates the hemopoietic injury and enhances the survival of mice irradiated with an additional "top-up" dose. It could be deduced that the single protective actions of the drugs retain their efficacy in repeated treatment and enhance the sparing effect of dose fractionation on hemopoiesis. Interestingly, the toxic side effects of the drugs tend to decrease when they are administered repeatedly, probably due to the development of tolerance to their cardiovascular action. This reduction in toxicity offers benefit with respect to the potential use of these hemopoiesis-protecting drugs in clinical radiotherapy.
The role of adenosine receptor agonists in regulation of hematopoiesis